Hennion & Walsh Asset Management Inc. Has $5.76 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Hennion & Walsh Asset Management Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,709 shares of the company's stock after selling 3,206 shares during the period. Hennion & Walsh Asset Management Inc.'s holdings in Johnson & Johnson were worth $5,756,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson during the 4th quarter worth about $32,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $33,000. Finally, Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $36,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded up $0.28 on Thursday, hitting $153.50. The company's stock had a trading volume of 5,288,204 shares, compared to its average volume of 7,929,036. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock's 50 day moving average is $153.81 and its 200-day moving average is $153.67. The company has a market capitalization of $369.32 billion, a PE ratio of 23.08, a PEG ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.39%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on JNJ shares. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Royal Bank of Canada reissued an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.